Further to intimation dated March 8, 2023, and pursuant to Regulation 5 (vii) of the SEBI (Buy-back of Securities) Regulations, 2018 (as amended) (‘Buyback Regulations’), Natco Pharma has informed that today on March 10, 2023 the Company has published the Public Announcement of buyback in Business Standard (English national daily newspaper, all editions), Business Standard (Hindi national daily newspaper, all editions) and Nava Telangana (Telugu daily newspaper, Hyderabad edition, Telugu being the regional language of Hyderabad where the registered office of the Company is situated). The soft copies of newspaper clippings of the Public Announcement are enclosed for the reference and dissemination on the BSE and NSE website.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: